NTBLQ

0.0001--
TP

Tuomo Patsi

Independent Chairman

Mr. Tuomo Patsi is Executive Chairman of the Board of Phi Pharma SA. Mr. Tuomo Patsi, MSci, is Independent Director of Notable Labs, Ltd since October 16, 2023 and serves as its Independent Chairman. He is Director of Aurealis Oy. He is Independent Non-Executive Director at Faron Pharmaceuticals Oy since March 24, 2023 and serves as its Independent Non-Executive Chairman since April 05, 2024. He served as Executive Vice President of Commercial International at Seagen Inc. (formerly known as Seattle Genetics, Inc.). since July 2020 until February 4, 2022. He had been President of EMEA Region at Celgene International Sárl since September 2014. Mr. Patsi served as Vice President of Europe at Human Genome Sciences Inc. since August 2010. Mr. Patsi served as Regional Vice President, Northern Europe at Celgene International. Mr. Patsi was one of the first employees in Celgene's European commercial organization, which was established in 2006 in anticipation of the launch of Revlimid (lenalidomide), an important treatment for multiple myeloma. At Celgene, Mr. Patsi held a number of leadership positions, including Head of European Marketing and General Manager of the Western European Region, as well as his most recent position as Regional Vice President, Northern Europe. Prior to joining Celgene, Mr. Patsi was with Amgen Inc. for many years, serving in a number of senior brand management and marketing positions, including Director of Global Marketing. He began his career as a Biomedical Research Scientist in Finland. Mr. Patsi held product management and clinical research positions in Europe with Rhone-Poulenc Rorer and Eli Lilly. Mr. Patsi is a registered pharmacist with a Master of Science degree in pharmacology from the Helsinki University School of Pharmacy, Finland.

Positions